Changes

Jump to navigation Jump to search
no edit summary
Line 14: Line 14:     
===Virus Genotypes===
 
===Virus Genotypes===
There are two antigenically distinct<sup>9</sup> genotypes of BVDV, type 1 and type 2, which are most accurately characterised based on sequence variation.  BVDV-1 and BVDV-2 contain 11 and 3 subtypes respectively, which have been demonstrated by analysis of the 5’UTR<sup>10</sup>. Despite the large antigenic differences between the genotypes, cross-protection against type 2 viruses is afforded by type 1 vaccines<sup>11, 12, 13</sup>.
+
There are two antigenically distinct<sup>9</sup> genotypes of BVDV, type 1 and type 2, which are most accurately characterised based on sequence variation.  BVDV-1 and BVDV-2 contain 11 and 3 subtypes respectively, which have been demonstrated by analysis of the 5’UTR<sup>10</sup>. Despite the large antigenic differences between the genotypes, some cross-protection against type 2 viruses is afforded by type 1 vaccines<sup>11, 12, 13</sup>.
   −
In general, the genotypes differ in virulence. BVDV-1 species are found worldwide and tend to cause milder disease <sup>14</sup>, whereas BVDV-2 isolates typically cause more severe disease which is often haemorrhagic and is associated with a high mortality rate<sup>11, 15</sup>. Type 2 viruses were first reported in Canada and the USA and have a more limited distribution than type 1 isolates. The relationship between genotype and virulence is, however, not fixed: some type 2 strains cause mild or subclinical disease<sup>16</sup>, and the spectrum disease caused by type 1 viruses is broad.
+
In general, the genotypes do not differ in virulence. It was, at one time, considered that BVDV-1 species which are found worldwide caused milder disease <sup>14</sup>, whereas BVDV-2 isolates typically caused more severe disease which is often haemorrhagic and was associated with a high mortality rate<sup>11, 15</sup>. This is no longer the case. The relationship between genotype and virulence is, however, not fixed: some type 2 strains cause mild or subclinical disease<sup>16</sup>, and the spectrum disease caused by type 1 viruses is broad. Type 2 viruses were first reported in Canada and the USA and have a more limited distribution than type 1 isolates.  
    
===Virus Biotypes===
 
===Virus Biotypes===
BVDV isolates from either genotype can be of a cytopathic or non-cytopathic biotype. Non-cytopathic (ncp) viruses produce no visible effects in cell culture, whereas infection with cytopathic (cp) viruses gives cell vacuolation and death. Although non-cytopathic isolates are responsible for the majority of BVDV infections worldwide, cytopathogenicity gives no indication of disease-causing potential. Cytopathic biotypes of bovine viral diarrhoea virus are always isolated alongside non-cytopathic strains, and are found in cases of mucosal disease, a fatal BVD-associated condition.  
+
BVDV isolates from either genotype can be of a cytopathic or non-cytopathic biotype. Non-cytopathic (ncp) viruses produce no visible effects in cell culture, whereas infection with cytopathic (cp) viruses gives cell vacuolation and death. Although non-cytopathic isolates are responsible for the majority of BVDV infections worldwide, cytopathogenicity gives no indication of disease-causing potential. Cytopathic biotypes of bovine viral diarrhoea virus are always isolated alongside non-cytopathic strains, and are found in cases of mucosal disease, a fatal BVD-associated condition<sup>46</sup>.
    
Cytopathic viruses originate from non-cytopathic strains by mutation, including viral gene rearrangements, duplications and deletions<sup>17</sup>, and insertions of cellular origin, such as ubiquitin sequences. Point mutations in the NS2 region and various RNA recombination events are also important<sup>18</sup>. Serologically, the two BVDV biotypes are indistinguishable, but on a molecular level cytopathic viruses produce an additional protein, NS3, not found in cells infected with non-cytopathic virus<sup>19, 20, 21</sup>. This marker molecule arises from when NS2-3, expressed in non-cytopathic isolates, is cleaved at a site created by the mutations above<sup>22</sup>.
 
Cytopathic viruses originate from non-cytopathic strains by mutation, including viral gene rearrangements, duplications and deletions<sup>17</sup>, and insertions of cellular origin, such as ubiquitin sequences. Point mutations in the NS2 region and various RNA recombination events are also important<sup>18</sup>. Serologically, the two BVDV biotypes are indistinguishable, but on a molecular level cytopathic viruses produce an additional protein, NS3, not found in cells infected with non-cytopathic virus<sup>19, 20, 21</sup>. This marker molecule arises from when NS2-3, expressed in non-cytopathic isolates, is cleaved at a site created by the mutations above<sup>22</sup>.
    
==Transmission and Epidemiology==
 
==Transmission and Epidemiology==
In most countries, BVDV is endemic and studies detecting antibody have estimated that between 70 and 100% of herds are either currently infected or have recently been infected with bovine viral diarrhoea virus<sup>23</sup>.
+
In most countries, BVDV is endemic and studies detecting antibody have estimated that between 70 and 100% of herds are either currently infected or have previously been infected with bovine viral diarrhoea virus<sup>23</sup>.
   −
BVDV can be transmitted from infected to susceptible cattle in several ways. Firstly, direct contact with an animal shedding BVDV in its secretions and excretions can cause disease. Virus is shed by both acutely and persistently infected (PI) animals but levels of shedding are much higher in persistently infected cattle, which are a natural reservoir for virus. It is estimated that the incidence of persistently infected animals may be as high as 1-2% of cattle less than one year of age. On a farm, PI cattle are often found in cohorts of similarly aged animals. This is because persistent infections arise when pregnant animals are acutely infected, and so an outbreak of acute, possibly subclinical, BVD in pregnant cattle can later result in a "batch" of PI calves.
+
BVDV can be transmitted from infected to susceptible cattle in several ways. Firstly, direct contact with an animal shedding BVDV in its secretions and excretions can cause disease. Virus is shed by both acutely and persistently infected (PI) animals but levels of shedding are much higher in persistently infected cattle, which are the natural reservoir for virus. It is estimated that the incidence of persistently infected animals is 1-2% of cattle less than one year of age and may be higher in infected herds. On a farm, PI cattle are often found in cohorts of similarly aged animals. This is because persistent infections arise when pregnant animals are acutely infected in early pregnancy, and so an outbreak of acute, possibly subclinical, BVD in pregnant cattle can later result in a "batch" of PI calves.
   −
Transmission to heifers and cows may also occur venereally or via artificial insemination as acutely and persistently infected bulls shed bovine viral diarrhoea virus in their semen<sup>24</sup>. The testes is an immunoprivileged site, and the virus can persist in this location despite otherwise systemic clearance<sup>25</sup>. Indirect spread is possible: BVDV has been shown to spread through the re-use of needles, nose tongs<sup>26</sup> and rectal gloves<sup>27</sup>, and blood feeding flies also give transmission.
+
Transmission to heifers and cows may also occur venereally, via artificial insemination or during embryo transfer, as acutely and persistently infected bulls shed bovine viral diarrhoea virus in their semen<sup>24</sup>. The testes is an immunoprivileged site, and the virus can persist in this location despite otherwise systemic clearance<sup>25</sup>. Indirect spread is possible: BVDV has been shown to spread through the re-use of needles, nose tongs<sup>26</sup> and rectal gloves<sup>27</sup>, and blood feeding flies also give transmission.
    
==Pathogenesis==
 
==Pathogenesis==
Line 34: Line 34:     
==Diagnosis==
 
==Diagnosis==
Although the clinical appearance may be suggestive of BVD, disease presentation can vary widely and so laboratory testing is usually necessary.
+
Clinical appearance of BVD infection is highly variable, often underlying many calf infections due to its immunosuppressive effect permitting secondary respiratory and enteric infection. Furthermore, the persistently infected calves can appear either unthrifty or perfectly normal. Therefore laboratory testing for the virus is essential.
    
===Clinical Signs===
 
===Clinical Signs===
The disease caused by bovine viral diarrhoea virus is known as bovine viral diarrhoea. It might be expected from this nomenclature that diarrhoea is a key clinical feature in BVDV infection, but disease can actually manifest in a variety of ways ranging from subclinical disease to muscosal disease. Virulence factors related to genotype and strain are partially responsible for these variations, but host factors are also important. Pregnancy status, stage of gestation, immunity and the level of development of the foetal immune system all contribute to the outcome of BVDV infection.
+
It might be expected from the nomenclature (bovine viral diarrhoea virus) that diarrhoea is a key clinical feature in BVDV infection, but it is not a major clinical sign. The clinical presentation can actually manifest in a variety of ways ranging from subclinical disease to the fatal muscosal disease<sup>34</sup>. Virulence factors related to genotype and strain are partially responsible for these variations, but host factors are also important. Pregnancy status, stage of gestation, immunity and the level of development of the foetal immune system all contribute to the outcome of BVDV infection.
    
====Acute Infections: Non-Pregnant Cattle====
 
====Acute Infections: Non-Pregnant Cattle====
In the naive, non-pregnant, immunocompetent animal, BVD is normally mild: it is estimated that 70 to 90% of BVDV infections cause no clinical signs<sup>30</sup>. If these subclinically affected cattle are observed closely, body temperature may marginally rise and mild leukopenia and agalactia may be seen <sup>31, 32</sup>. When clinical disease does occur in these animals, morbidity is high amongst cattle of 6-12 months of age. Following a 5-7 day incubation period, pyrexia and leukopenia is seen. Viraemia arises on days 4-5 days post-infection, and continues until around day 15<sup>33</sup>. Although some cattle suffer diarrhoea in BVDV infection, the disease no longer seems to present as herd outbreaks of diarrhoea<sup>34</sup>. Clinical signs more commonly include depression, anorexia, occulo-nasal discharge, decreased milk production and oral lesions<sup>35</sup>, with a rapid respiratory rate resembling pneumonia sometimes apparent<sup>31</sup>. Acutely infected, non-pregnant animals shed low concentrations of virus compared to persistently infected cattle<sup>33</sup>, and antibodies are produced 2-4 weeks post-infection which persist for life<sup>35</sup>.
+
In the naive, non-pregnant, immunocompetent animal, BVD is normally mild: it is estimated that 70 to 90% of BVDV infections cause no obvious clinical signs<sup>30</sup>. If these subclinically affected cattle are observed closely, body temperature may marginally rise and mild leukopenia and agalactia may be seen <sup>31, 32</sup>. When clinical disease does occur in these animals, morbidity is high amongst cattle of 6-12 months of age. Following a 5-7 day incubation period, pyrexia and leukopenia is seen. Viraemia arises on days 4-5 days post-infection, and continues until around day 15<sup>33</sup>. Although some cattle suffer diarrhoea in BVDV infection, the disease no longer seems to present as herd outbreaks of diarrhoea<sup>34</sup>. Clinical signs more commonly include depression, anorexia, occulo-nasal discharge, decreased milk production and oral lesions<sup>35</sup>, with a rapid respiratory rate resembling pneumonia sometimes apparent<sup>31</sup>. Acutely infected, non-pregnant animals shed low concentrations of virus compared to persistently infected cattle<sup>33</sup>, and antibodies are produced 2-4 weeks post-infection which persist for many years<sup>35</sup>.
    
Acute BVDV infection causes a significant leukopenia, hampering the host's defences against invading pathogens. This BVDV-associated immunosupression has a particularly important role in bovine respiratory disease: an association has been demonstrated between BVDV antibody titre and treatment for respiratory disease<sup>36</sup>. BVDV is the virus most frequently isolated from pneumonic lungs and is often found in association with ''[[Pasteurella haemolytica]]''<sup>35</sup>, causing severe fibrino-purulent bronchopneumonia and increasing the total lesion area by 35-60% compared to pasteurellosis alone<sup>34</sup>. Synergism is also displayed with [[Bovine Parainfluenza - 3|parainfluenza]], bovine rhinotracheitis and [[Bovine Respiratory Syncytial Virus|respiratory syncitial viruses]].
 
Acute BVDV infection causes a significant leukopenia, hampering the host's defences against invading pathogens. This BVDV-associated immunosupression has a particularly important role in bovine respiratory disease: an association has been demonstrated between BVDV antibody titre and treatment for respiratory disease<sup>36</sup>. BVDV is the virus most frequently isolated from pneumonic lungs and is often found in association with ''[[Pasteurella haemolytica]]''<sup>35</sup>, causing severe fibrino-purulent bronchopneumonia and increasing the total lesion area by 35-60% compared to pasteurellosis alone<sup>34</sup>. Synergism is also displayed with [[Bovine Parainfluenza - 3|parainfluenza]], bovine rhinotracheitis and [[Bovine Respiratory Syncytial Virus|respiratory syncitial viruses]].
   −
Although BVDV infections in naive, non-pregnant animals are usually mild, outbreaks of a severe form of BVD have been known<sup>11, 37</sup>. These were characterised by the acute onset of diarrhoea, pyrexia and milk drop, with some cases proving fatal. These oubtreaks were associated with genotype 2 viruses, and it transpired vaccination with type 1 vaccines had not afforded cross-protection in these instances due to non-compliance with instructions. Generally, BVDV-2 infection is seen less frequently than disease related to type 1 virus, but is associated with haemorrhagic syndrome. Haemorrhagic syndrome is characterised by severe thrombocytopaenia leading to haematochezia, petechiation and epistaxis<sup>38</sup> and has been described in both Europe and North America. Severe disease is also possible with virulent type 1 infection, presenting as high fever, oral ulcerations, eruptive lesions of the coronary band and interdigital cleft, diarrhoea, dehydration, leukopenia, and thrombocytopenia. Thrombocytopenia may give petechiation of  the conjunctiva, sclera, nictitating membrane and the mucosal surfaces of the mouth and vulva, as well as prolonged bleeding from injection sites<sup>39</sup>.
+
BVDV infections in naive, non-pregnant animals are usually mild; however outbreaks of a severe form of BVD became evident in the late 1980s in the USA and Canada<sup>11, 37</sup>. These were characterised by the acute onset of diarrhoea, pyrexia and milk drop, with some cases proving fatal. These oubtreaks were associated with genotype 2 viruses, and it transpired vaccination with type 1 vaccines had afforded poor cross-protection in these instances due to non-compliance with instructions. Initially, BVDV-2 infection was seen less frequently than disease related to type 1 virus, but was associated with a haemorrhagic syndrome. The haemorrhagic syndrome is characterised by severe thrombocytopaenia leading to haematochezia, petechiation and epistaxis<sup>38</sup> and has now been described in both Europe and North America. Severe disease is also possible with virulent type 1 infection, presenting as high fever, oral ulcerations, eruptive lesions of the coronary band and interdigital cleft, diarrhoea, dehydration, leukopenia, and thrombocytopenia. Thrombocytopenia may give petechiation of  the conjunctiva, sclera, nictitating membrane and the mucosal surfaces of the mouth and vulva, as well as prolonged bleeding from injection sites<sup>39</sup>.
    
====Acute Infections: Pregnant Animals====
 
====Acute Infections: Pregnant Animals====
When acute BVDV infection occurs during pregnancy, the dam may show any of the clinical manifestations that are seen in non-pregnant animals. BVDV is able to cross the placenta and infect the developing foetus and so there may be additional outcomes of infection that depend on the stage of gestation. If infection becomes established at the time of insemination, conception rates may be reduced, and early embryonic death is increased when the virus is introduced at a slightly later stage<Sup>40, 41</sup>.  '''Foetal infection in the first trimester (50-100 days)''' may also result in '''death''', although expulsion of the foetus often does not occur until several months later.
+
When acute BVDV infection occurs during pregnancy, the dam may show any of the clinical manifestations that are seen in non-pregnant animals. BVDV is able to cross the placenta and infect the developing foetus and so there may be additional outcomes of infection that depend on the stage of gestation. If infection becomes established at the time of insemination, conception rates may be reduced, and early embryonic death is increased when the virus is introduced at a slightly later stage<Sup>40, 41</sup>.  '''Foetal infection in the first trimester (50-100 days)''' may also result in '''death''', although expulsion of the foetus often does not occur until several months later. An additional effect of foetal infection before 120 days gestation is the birth of '''persistently infected (PI) calves'''.
    
'''Congenital defects''' can arise from transplacental infection '''between days 100 and 150'''. This is caused by an inappropriate inflammatory response mounted to BVDV by the immune system, which is undergoing the final phase of development at this stage<sup>33</sup>. Examples of common congenital abnormalities include defects of the thymus, ocular changes and cerebellar hypoplasia<sup>34</sup>. Calves with cerebellar hypoplasia ataxic, reluctant to stand and may suffer tremors<sup>35</sup>, and ocular pathology often causes blindness and cataracts. Localisation of virus to the vascular endothelium gives vasculitis, leading to oedema, hypoxia and cellular degeneration. Weak, stunted calves may also be produced by BVDV infection in the second trimester.
 
'''Congenital defects''' can arise from transplacental infection '''between days 100 and 150'''. This is caused by an inappropriate inflammatory response mounted to BVDV by the immune system, which is undergoing the final phase of development at this stage<sup>33</sup>. Examples of common congenital abnormalities include defects of the thymus, ocular changes and cerebellar hypoplasia<sup>34</sup>. Calves with cerebellar hypoplasia ataxic, reluctant to stand and may suffer tremors<sup>35</sup>, and ocular pathology often causes blindness and cataracts. Localisation of virus to the vascular endothelium gives vasculitis, leading to oedema, hypoxia and cellular degeneration. Weak, stunted calves may also be produced by BVDV infection in the second trimester.
   −
Infection in the '''third trimester trimester (over 180-200 days)''' elicits a response from the fully-developed immune system, giving rise to '''normal but seropositive calves'''. An additional effect of foetal infection before 120 days gestation is the birth of '''persistently infected (PI) calves'''.
+
Infection in the '''third trimester trimester (over 180-200 days)''' elicits a response from the fully-developed immune system, giving rise to '''normal but seropositive calves'''.
    
====Persistent Infections====
 
====Persistent Infections====
Foetal infection with a non-cytopathic BVDV virus before 120 days gestation may result in the birth of calves persistently infected with and tolerant to bovine viral diarrhoea virus. At this stage in gestation, the immune system is partially competent and recognises the BVDV antigen as self, meaning that no response is mounted. The calf therefore becomes tolerant to the virus which persists into neonatal life. Persistently infected animals can be identified at birth as being antigen-positive but seronegative. However, colostral transfer of maternal immunity or infection with a heterologous strain of BVDV can make these animals seropostitive, so care must be taken when timing and interpreting tests<sup>42</sup>.
+
Foetal infection with a non-cytopathic BVDV virus before 120 days gestation may result in the birth of calves persistently infected with and tolerant to bovine viral diarrhoea virus. At this stage in gestation, the immune system is partially competent and recognises the BVDV antigen as self, meaning that no response is mounted. The calf therefore becomes tolerant to the virus which persists into neonatal life<sup>46</sup>. Persistently infected animals can be identified at birth as being antigen-positive but seronegative. However, colostral transfer of maternal immunity or infection with a heterologous strain of BVDV can make these animals seropostitive, so care must be taken when timing and interpreting tests<sup>42</sup>.
    
Persistently infected animals continuously shed large amounts of virus throughout their lives, providing a major source of infection for naive cattle<sup>23</sup>. Persistently infected dams produce persistently infected calves, resulting in family lines capable of maintaining the virus in a herd<sup>35</sup>. It is estimated that 1-2% of the cattle population and up to 13% of foetal calves are persistently infected<sup>34</sup>.
 
Persistently infected animals continuously shed large amounts of virus throughout their lives, providing a major source of infection for naive cattle<sup>23</sup>. Persistently infected dams produce persistently infected calves, resulting in family lines capable of maintaining the virus in a herd<sup>35</sup>. It is estimated that 1-2% of the cattle population and up to 13% of foetal calves are persistently infected<sup>34</sup>.
   −
50% of persistently infected cattle die within the first year of life<Sup>33</sup>. Animals may be undersized and slow-growing, and are predisposed to other diseases<sup>43</sup>. Persistent infection with BVDV is the prerequisite for developing mucosal disease.
+
50% of persistently infected cattle die within the first year of life<Sup>33</sup>. Animals may be undersized and slow-growing, and are predisposed to other diseases<sup>43</sup>. Persistent infection with BVDV is the prerequisite for developing mucosal disease<sup>46</sup>.
    
====Mucosal Disease====
 
====Mucosal Disease====
Line 68: Line 68:  
There are several techniques available for the laboratory diagnosis of BVD. These can detect antibody to BVDV or parts of the virus itself.
 
There are several techniques available for the laboratory diagnosis of BVD. These can detect antibody to BVDV or parts of the virus itself.
   −
Tests that detect anti-BVDV antibody include the serum neutralisation test, and an ELISA<sup>34</sup>. The serum neutralisation test depends on the ability of antibodies in the serum to neutralise BVD virus and thereby prevent infection of cell culture. The test takes four to seven days and requires cell culture facilities and an experienced observer. The ELISA detects anti-BVDV antibody when it binds to a specific viral antigen. The test is completed within one day and is simple to perform. Because antibody against BVDV is prevalent in most cattle populations, a single serologic test is not usually sufficient for diagnosis. Therefore, an increase in antibody titre between paired serum samples must be more than four-fold to confirm recent infection<sup>39</sup>.
+
Tests that detect anti-BVDV antibody include the serum neutralisation test, and an ELISA<sup>34</sup>. The serum neutralisation test depends on the ability of antibodies in the serum to neutralise BVD virus and thereby prevent infection of cell culture. The test takes four to seven days and requires cell culture facilities and an experienced observer. The ELISA can detect either BVDV antibody or BVDV antigen. The BVDV ELISA test can be completed within hours and is simple to perform. Because antibody against BVDV is prevalent in most cattle populations, a single serologic test is not usually sufficient for diagnosis of a recent infection. Therefore, an increase in antibody titre between paired serum samples must be more than four-fold to confirm recent infection<sup>39</sup>.
   −
Viral antigen or RNA can be detected using clinical specimens or tissue samples. Bovine viral diarrhoea virus can be isolated from blood, nasal swabs or tissues to confirm active infection, and demonstration of virus in samples obtained at least three weeks apart is suggestive of persistent infection. The best tissues for virus isolation are spleen, lymph node and segments of the gastrointestinal tract showing ulcerative lesions. An antigen-capture [[ELISA]] is also available to detect the presence of BVDV antigen in blood or serum, and immunohistochemistry will demonstrate the presence of antigen in fixed or frozen sections. Viral RNA may also be detected, using PCR for clinical specimens and PCR or ''in situ'' hybridisation on fresh or fixed tissues<sup>39</sup>.  
+
Viral antigen or RNA can be detected using clinical specimens or tissue samples. Bovine viral diarrhoea virus can be isolated from blood, nasal swabs or tissues to confirm active infection, and demonstration of virus in samples obtained at least three weeks apart is suggestive of persistent infection. The best tissues for virus isolation are skin, spleen, lymph node and segments of the gastrointestinal tract showing ulcerative lesions. An antigen-capture [[ELISA]] is also available to detect the presence of BVDV antigen in blood or serum. The ELISA for BVDV antigen will detect viral infection and is widely used to diagnose persistently infected calves. Two samples taken 3-4 weeks apart will confirm a persistent infection. Immunohistochemistry will demonstrate the presence of antigen in fixed or frozen sections. Viral RNA may also be detected, using PCR for clinical specimens or ''in situ'' hybridisation on fresh or fixed tissues<sup>39</sup>.  
   −
Genotype is generally determined by PCR or nucleic acid sequencing.
+
Genotype is generally determined by PCR with subsequent nucleic acid sequencing.
 
[[Image:BVD-MD.gif|right|thumb|150px|Small erosions of MDV/BVDV - vesicles are microscopic (Courtesy of Alun Williams, RVC)]]
 
[[Image:BVD-MD.gif|right|thumb|150px|Small erosions of MDV/BVDV - vesicles are microscopic (Courtesy of Alun Williams, RVC)]]
 
===Pathology===
 
===Pathology===
Line 78: Line 78:  
In cases of mild, acute BVD, lesions are rarely seen. When disease is more severe, the lymph nodes may appear swollen, there may be erosions and ulcerations of the gastrointestinal tract tract and serosal surfaces of the viscera may show petechial and ecchymotic hemorrhages<sup>39</sup>.
 
In cases of mild, acute BVD, lesions are rarely seen. When disease is more severe, the lymph nodes may appear swollen, there may be erosions and ulcerations of the gastrointestinal tract tract and serosal surfaces of the viscera may show petechial and ecchymotic hemorrhages<sup>39</sup>.
   −
The pathology associated with mucosal disease is much more striking<sup>34</sup>. Oral, lingual and buccal erosions are observed, and buccal lesions often coalesce to form larger areas of necrosis and sloughed epithelium. Oesophageal lesions present similarly. The gastrointestinal tract often shows characteristic pathology, but post-mortem examination must be performed soon after death so that these are not masked by autolytic changes. In the rumen, ulceration is rare but congestion and oedema may be seen along the pillars, and papillae can be reduced in size. Several discoid erosions of around 5mm in diameter appear in the abomasum, with hyperaemia of the surrounding mucosa and petechiation of the submucosa, particularly at the pylorus. Abomasal erosions occasionally enlarge and ulcerate. Oval erosions can be seen along the antimesenteric surface of the small intestine, overlying the lymphatic tissue of the Peyer's patches and measuring 2-5 centimetres in length. The erosions become larger (10-20 centimetres) and more numerous towards the terminal ileum, and the exposed surfaces varies in appearance. In more chronic lesions, food is seen to adhere to the underlying submucosa, and in acute disease the exposed surface is acutely congested and often haemorrhages into the gut lumen. In the large intestine, the mucosal folds may be thickened, giving the organ a striped appearance inwardly. Petechiation and erosions are occasionally seen along the folds, and the large intestinal contents are watery, dark and foul-smelling.
+
The pathology associated with mucosal disease is much more striking<sup>34</sup>. Oral, lingual and buccal erosions are observed, and buccal lesions often coalesce to form larger areas of necrosis and sloughed epithelium. Oesophageal lesions present similarly. The gastrointestinal tract often shows characteristic pathology, but post-mortem examination must be performed soon after death so that these are not masked by autolytic changes. In the rumen, ulceration is less common but, with congestion and oedema, may be seen along the pillars, and papillae can be reduced in size. Several discoid erosions of around 5mm in diameter appear in the abomasum, with hyperaemia of the surrounding mucosa and petechiation of the submucosa, particularly at the pylorus. Abomasal erosions occasionally enlarge and ulcerate. Oval erosions can be seen along the antimesenteric surface of the small intestine, overlying the lymphatic tissue of the Peyer's patches and measuring 2-5 centimetres in length. The erosions become larger and more numerous towards the terminal ileum, and the exposed surfaces varies in appearance. In more chronic lesions, food is seen to adhere to the underlying submucosa, and in acute disease the exposed surface is acutely congested and often haemorrhages into the gut lumen. In the large intestine, the mucosal folds may be thickened, giving the organ a striped appearance inwardly. Petechiation and erosions are occasionally seen along the folds, and the large intestinal contents are watery, dark and foul-smelling.
    
==Treatment and Control==
 
==Treatment and Control==
Acute BVDV infection is usually mild and does not require treatment, and treatment of more severe cases is symptomatic and supportive. There is no known treatment for mucosal disease and cases are often euthanased on welfare grounds.
+
Acute BVDV infection is usually mild and does not require treatment, and treatment of more severe cases is symptomatic and supportive. There is no known treatment for mucosal disease and cases are euthanased on welfare grounds; recovery is most unlikely.
   −
Control of BVD is practiced to a greater extent than treatment. The aim is eradication on individual farms but some countries, for example in Scandinavia, have achieved national eradication. There are several elements to control, including effective biosecurity, elimination of persistently infected animals, and vaccination strategies<sup>39</sup>.
+
Control of BVD is practiced to a greater extent than treatment. The aim is eradication on individual farms but some countries, for example in Scandinavia, have achieved national eradication. There are several elements to control, including effective biosecurity, strategic testing, elimination of persistently infected animals, and vaccination strategies<sup>39</sup>.
    
Biosecurity measures can include the usual hygiene precautions taken on farms, by visitors and during veterinary attention, as well as scrutiny of bought-in livestock and biologicals. Replacement cattle should be tested for persistent infection and quarantined on-farm in case of acute infections before entering the herd. If the resident herd is BVD-vaccinated, new animals should be brought up to date before joining the cohort. Embryo donors should be tested for persistent infection before transfer occurs, and purchase of in-calf heifers should be avoided as their offspring may be persistently infected. BVDV is shed in semen, so breeding bulls and semen for artificial insemination should be tested before coming into contact with cows.
 
Biosecurity measures can include the usual hygiene precautions taken on farms, by visitors and during veterinary attention, as well as scrutiny of bought-in livestock and biologicals. Replacement cattle should be tested for persistent infection and quarantined on-farm in case of acute infections before entering the herd. If the resident herd is BVD-vaccinated, new animals should be brought up to date before joining the cohort. Embryo donors should be tested for persistent infection before transfer occurs, and purchase of in-calf heifers should be avoided as their offspring may be persistently infected. BVDV is shed in semen, so breeding bulls and semen for artificial insemination should be tested before coming into contact with cows.
Line 89: Line 89:  
A protocol for screening cattle herds for persistent infection should be implemented. Testing can be achieved by virus isolation or antigen-capture ELISA from serum or buffy coat cells, or by antigen detection in skin biopsies. The selected programme should be designed around the type and size of herd, financial limitations and the techniques available at the chosen diagnostic laboratory. Once identified, persistently infected animals should be culled as soon as possible.
 
A protocol for screening cattle herds for persistent infection should be implemented. Testing can be achieved by virus isolation or antigen-capture ELISA from serum or buffy coat cells, or by antigen detection in skin biopsies. The selected programme should be designed around the type and size of herd, financial limitations and the techniques available at the chosen diagnostic laboratory. Once identified, persistently infected animals should be culled as soon as possible.
   −
Both modified live and beta-propiolactone inactivated BVDV vaccines are available for used. Although cross-protection between strains and genotypes is generally good, antigenic diversity among challenge viruses may affect the efficacy of a given vaccine. Because BVDV is tropic for the foetus, modified live vaccines should not be used in pregnant animals. The virus is also immunosuppressive and so vaccination of animals showing signs of disease is not recommended. Maternally-derived antibody wanes at 3-6 months of age, and so to ensure that vaccination induces a protective immune response animals should be vaccinated (or re-vaccinated) after this age.
+
Both modified live (not in the UK) and chemically-inactivated BVDV vaccines are available for use. Although cross-protection between strains and genotypes is generally good, antigenic diversity among challenge viruses may affect the efficacy of a given vaccine. Because BVDV is tropic for the foetus, modified live vaccines should not be used in pregnant animals. The virus is also immunosuppressive and so modified-live vaccination of animals showing signs of disease is not recommended. Maternally-derived antibody wanes at 3-6 months of age, and so to ensure that vaccination induces a protective immune response animals should be vaccinated (or re-vaccinated) by this age.
    
==Links==
 
==Links==
Line 141: Line 141:  
#Baker, J (1995) The Clinical Manifestations of Bovine Viral Diarrhea Infection. ''The Veterinary Clinics of North America: Food Animal Practice'', '''11(3)''', 425-445.
 
#Baker, J (1995) The Clinical Manifestations of Bovine Viral Diarrhea Infection. ''The Veterinary Clinics of North America: Food Animal Practice'', '''11(3)''', 425-445.
 
#Martin, S W and Bohac, J G (1986) The association between serologic titers in infectious bovine rhinotracheitis virus, bovine virus diarrhea virus, parainfluenza-3 virus, respiratory syncitial virus and the treatment for respiratory disease in Ontario feeder calves. ''Canadian Journal of Veterinary Research'', '''50''', 351-358.
 
#Martin, S W and Bohac, J G (1986) The association between serologic titers in infectious bovine rhinotracheitis virus, bovine virus diarrhea virus, parainfluenza-3 virus, respiratory syncitial virus and the treatment for respiratory disease in Ontario feeder calves. ''Canadian Journal of Veterinary Research'', '''50''', 351-358.
#Hibberd, R C and Turkington, A (1993) Fatal bovine viral diarrhoea virus infection of adult cattle. ''Veterinary Record'', '''132''', 227-228.
+
#Hibberd, R C, Turkington, A & Brownlie, J.(1993) Fatal bovine viral diarrhoea virus infection of adult cattle. ''Veterinary Record'', '''132''', 227-228.
 
#Rebhun, W C et al (1989) Thrombocytopenia associated with bovine viral diarrhoea infection in cattle. ''Journal of Veterinary Internal Medicine'', '''3''', 42-46.
 
#Rebhun, W C et al (1989) Thrombocytopenia associated with bovine viral diarrhoea infection in cattle. ''Journal of Veterinary Internal Medicine'', '''3''', 42-46.
 
#Merck & Co (2008) '''The Merck Veterinary Manual (Eighth Edition)''', ''Merial''.
 
#Merck & Co (2008) '''The Merck Veterinary Manual (Eighth Edition)''', ''Merial''.
Line 150: Line 150:  
#Brownlie, J et al (2000) Bovine virus diarrhoea virus- strategic decisions for diagnosis and control. ''In Practice'', '''22(4)''', 176-187.
 
#Brownlie, J et al (2000) Bovine virus diarrhoea virus- strategic decisions for diagnosis and control. ''In Practice'', '''22(4)''', 176-187.
 
#Brownlie, J (1990) Pathogenesis of mucosal disease and molecular aspects of bovine virus diarrhoea virus. ''Veterinary Microbiology'', '''23''', 371-382.
 
#Brownlie, J (1990) Pathogenesis of mucosal disease and molecular aspects of bovine virus diarrhoea virus. ''Veterinary Microbiology'', '''23''', 371-382.
 
+
#Brownlie, J., Clarke, M. & Howard, C. (1984) Experimental production of fatal mucosal disease in cattle. ''Veterinary Record'', '''114''', 535-536
    
{{review}}
 
{{review}}
1,454

edits

Navigation menu